Credits: Canva
The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.
It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.
The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.
In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.
TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."
Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.
While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.
Credit: iStock
A diarrheal illness caused by the parasite Cyclospora cayetanensis is spreading across multiple US states, with federal health officials reporting a higher-than-expected number of cyclosporiasis cases this summer. While several outbreaks have been identified, investigators have yet to pinpoint a common source.
The US Centers for Disease Control and Prevention (CDC) is investigating clusters of infections in Illinois, New York, Pennsylvania, Texas, Michigan, Ohio, Alabama, Kentucky, Tennessee, Virginia and West Virginia. Some clusters have been linked to Mexican-style restaurants, a grocery chain and a catered event, but officials say there is no evidence yet that they are part of a single nationwide outbreak, CNN reported.
Meanwhile, the US Food and Drug Administration (FDA) is tracing fresh produce, including white and green onions, cucumbers and cilantro, as potential sources of contamination.
Michigan has reported the largest outbreak so far. As of July 6, the state had confirmed 678 cases of cyclosporiasis, according to the Michigan Department of Health and Human Services (MDHHS). The state typically records around 50 cases annually, making this year's outbreak more than 13 times higher than normal.
Ohio has also seen a sharp rise, reporting 177 cases as of July 2. Nearly 171 of those infections were recorded after June 20, with cases confirmed across 43 counties.
Nationally, excluding Michigan, the CDC reported 145 confirmed cases across 17 states between May 1 and June 16. At least 20 people have been hospitalized, though no deaths have been reported. Patients ranged in age from 5 to 86 years, with a median age of 42, and about 61% of cases were reported in women.
Experts say Cyclospora cayetanensis is much harder to trace than common foodborne bacteria such as E. coli and Salmonella.
Investigators often rely on DNA fingerprinting to connect bacterial infections to contaminated food through laboratory networks such as PulseNet. However, this approach is far less effective for Cyclospora because the parasite has a far more complex genetic makeup, making it difficult to link cases to a single food item or supplier.
Dr. Max Teplitski, former head of the Division of Food Safety at the US Department of Agriculture and now chief science officer at the International Fresh Produce Association, said the parasite remains one of the most difficult foodborne pathogens to investigate, contributing to delays in identifying the outbreak source, CNN reported.
The CDC recommends the following precautions to reduce the risk of infection:
Cyclospora spreads through food or water contaminated with human feces and is not transmitted directly from person to person.
Dr. Darien Sutton, an emergency medicine physician and ABC News medical correspondent, stressed that proper handwashing is essential because alcohol-based hand sanitizers are not effective against the parasite.
"This type of parasite doesn't easily go away with alcohol-based hand sanitizer. So, good old handwashing is really key here," Sutton said.
Credit: FDA
The US Food and Drug Administration (FDA) has announced a recall of organic frozen blueberries sold at Publix stores across eight US states after they were linked to a potential outbreak of E. coli infections.
GreenWise Organic IQF Blueberries were first recalled by Frutas y Hortalizas del Sur S.A. of San Carlos, Chile, which supplied the product to grocery chain Publix. Publix then recalled the frozen blueberries from its stores on July 3, 2026, according to a company statement.
According to FDA, the outbreak has resulted in 12 confirmed cases of E. coli-related gastrointestinal illness, including four hospitalizations. The FDA also said it has received reports of illness after consumers ate the frozen blueberries.
While many strains of E. coli are harmless, the bacteria involved in this recall is Shiga toxin-producing E. coli (STEC).
"E. coli O145 is a Shiga toxin-producing E. coli (STEC) that can cause illness characterised by severe stomach cramps, diarrhoea (which may be bloody), and vomiting," the FDA said.
The agency added that although most healthy people recover within a week, some infections can lead to hemolytic uremic syndrome (HUS), a serious complication that can cause kidney damage, particularly in young children, older adults, and people with weakened immune systems.
Also read: Why Fentanyl Addiction Treatments Are Losing Effectiveness, Study Finds
The recalled blueberries were distributed to Publix stores in:
The FDA advises consumers to check their freezers for the following product:
Consumers who have the affected product should not eat it. Frutas y Hortalizas del Sur S.A. said it is working closely with regulatory authorities and customers. The company has instructed all customers who received the affected lot to immediately isolate the product, stop distributing it, and notify any downstream customers.
Escherichia coli (E. coli) is a group of bacteria that normally lives in the intestines of humans and animals. Most strains are harmless and help with digestion. However, certain strains produce toxins that can cause serious illness when ingested through contaminated food or water.
An E. coli infection most commonly affects the digestive system, causing:
Some infections, particularly those caused by Shiga toxin-producing E. coli, can lead to hemolytic uremic syndrome (HUS), a potentially life-threatening condition that damages the kidneys.
You can reduce your risk of E. coli infection by:
Credit: AI
The single overnight sleep study, usually conducted to diagnose obstructive sleep apnea (OSA) may not be accurate enough, according to a recent study. Sleep patterns change significantly from one night to the next, meaning current one-night testing could underdiagnose or overestimate the condition in some patients.
The study, published in the journal npj Digital Medicine, challenges the long-standing practice of relying on a single overnight sleep study, also known as polysomnography, to diagnose OSA.
Obstructive sleep apnea is a common sleep disorder in which breathing repeatedly stops and starts during sleep due to blockage of the upper airway. If left untreated, it has been linked to serious health problems, including high blood pressure, cardiovascular disease, type 2 diabetes, stroke, and reduced quality of life.
To investigate whether a single sleep study accurately reflects a person's condition, researchers studied about 100 adults for suspected sleep apnea.
Participants underwent standard overnight polysomnography, a gold-standard diagnostic test. Simultaneously, they also had their sleep monitored repeatedly over several weeks in their home environment.
The researchers then compared the results from the one-night test with the average findings collected across multiple nights.
The analysis revealed significant night-to-night variation in sleep apnea severity. In many cases, the severity measured during one laboratory night did not match the average severity recorded over multiple nights.
As a result, some patients could get classified into the wrong severity category due to the one-night test, particularly those whose sleep apnea naturally fluctuates or whose sleep is easily affected by the unfamiliar environment.
Lead author Dr Bastien Lechat, a sleep expert at FHMRI Sleep Health, said, “Our findings show that sleep apnea can vary considerably from one night to the next, so if you only measure it once, you may not capture the true severity of the condition. In some participants, we saw clear differences between the single-night result and the average across multiple nights, which suggests current diagnostic approaches may under- or overestimate disease severity in some individuals.”
The researchers also found that patients whose classifications changed between the types of tests often experienced poorer sleep during laboratory testing. This indicated that an unfamiliar sleep environment may alter sleep quality and influence results.
Senior author Professor Sutapa Mukherjee, Professor of Respiratory and Sleep Medicine at Flinders University and Senior Consultant at Southern Adelaide Local Health Network (SALHN), said, “Our findings show that sleep apnea is a dynamic disorder, and by capturing how it changes over time, we can build a much more accurate and clinically meaningful picture of a patient's condition.”
The researchers also believe that monitoring sleep on multiple nights can help doctors assess a patient's future health risks and course of treatment in a better way.
While further research is needed before multi-night monitoring becomes routine clinical practice, the authors believe the study marks an important step toward modernizing sleep apnea diagnosis.
© 2024 Bennett, Coleman & Company Limited